TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30240280
Drug: MBIR at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBIR at low dose (NI 20)
Study: 27763682
Drug: Opicapone (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone (5, 15, and 30 mg)
Study: 27763682
Drug: Opicapone (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone (5, 15, and 50 mg)
Study: 25074885
Drug: Cinnamon ointment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon ointment, 2 mL every 12 h for 10 days
Study: 25074885
Drug: Placebo ointment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment, 2 mL every 12 h for 10 days
Study: 17517342
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum levels of apolipoprotein A-I (< 103 mg/dL)
Study: 15133010
Drug: End-exercise pH
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-exercise pH across treatments
Study: 11868527
Drug: Permanent magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Permanent magnetic field (induction 60 mT) treatment
Study: 1805138
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid combination
Study: 28500678
Drug: BGG492 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGG492 150 mg t.i.d.
Study: 28500678
Drug: BGG492 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGG492 100 mg t.i.d.
Study: 28500678
Drug: BGG492 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGG492 (both doses) during open-label extension study
Study: 28500678
Drug: BGG492 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGG492 150 mg
Study: 22010227
Drug: D2 agonist
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 agonist
Study: 22010227
Drug: D2 receptor
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 receptor antagonist
Study: 22010227
Drug: D1 receptor
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1 receptor antagonist
Study: 19895679
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment program (dose-matched)
Study: 12827350
Drug: Alcohol (256
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (256 g per day)
Study: 8450998
Drug: Low-dose apomorphine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose apomorphine (0.01 mg/kg) SC
Study: 25333245
Drug: Potassium nitrate
Normalized name: Potassium Nitrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium nitrate (PN) 450 mg per day
Study: 8792921
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (SIT) with Parietaria extract
Study: 1599300
Drug: Cisapride (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (0.8 mg/kg/day)
Study: 30004916
Drug: Bone marrow-derived
Normalized name: Allogeneic human bone marrow-derived mpc
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow-derived mononuclear cells (BM-MNCs) injected intramuscularly at 40 locations of the calf muscle (500-700 mL harvested, 40 mL concentrated).
Study: 26613203
Drug: PC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC treatment as usual (control group)
Study: 25138064
Drug: Full-dose almonds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose almonds (50-100 g/d)
Study: 25138064
Drug: Half-dose almonds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose almonds with half-dose muffins
Study: 24925120
Drug: Full-dose muffins
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose muffins
Study: 22762147
Drug: NOMAC/E2 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4‐day regimen (n= 56)
Study: 22762147
Drug: LNG/EE (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG/EE (150 μg/30 μg) in a 21/7‐day regimen (n= 54)
Study: 20085939
Drug: sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib 400 mg twice daily
Study: 24080250
Drug: Montelukast treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast treatment
Study: 11870962
Drug: Preventive oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive oral hygiene program (professional tooth cleaning, dental health information, and oral hygiene instruction) over a 6-month period
Study: 11870962
Drug: Preventive oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive oral hygiene program
Study: 11686668
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol treatment for 24 hours
Study: 11686668
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) with transdermal oestradiol and medroxyprogesterone for 6 weeks
Study: 7930300
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 25 micrograms twice daily
Study: 8879892
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 100 micrograms twice daily
Study: 8879892
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 500 micrograms twice daily
Study: 16393726
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (all doses)
Study: 12799091
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg/d
Study: 2439783
Drug: Bisoprolol 10
Normalized name: bisoprolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 10 mg/d
Study: 25012727
Drug: Subcutaneous pasireotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous pasireotide (300, 600, or 900 μg)
Study: 25012727
Drug: Intramuscular pasireotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular pasireotide long-acting release (20, 40, or 60 mg)
Study: 25012727
Drug: Subcutaneous pasireotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous pasireotide
Study: 25012727
Drug: Intramuscular pasireotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular pasireotide long-acting release
Study: 17143047
Drug: Over-the-counter multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-the-counter multivitamin supplements containing vitamin K1
Study: 16274381
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg 17‐beta estradiol for 36 months
Study: 12018742
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose Therapy (HDT)
Study: 12018742
Drug: Conventional Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Chemotherapy (CCT)
Study: 7587973
Drug: AUDADIS drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: AUDADIS drug module
Study: 2078484
Drug: Intensification-discontinuation arm
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification-discontinuation arm (B)
Study: 29749718
Drug: Test acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test acetaminophen product available in Mexico
Study: 29749718
Drug: Reference 500‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference 500‐mg acetaminophen product
Study: 24728665
Drug: Peretinoin 600
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peretinoin 600 mg/day
Study: 24728665
Drug: Peretinoin 300
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peretinoin 300 mg/day
Study: 23668921
Drug: Postoperative subacromial
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative subacromial infusion catheter filled with 0.5% bupivacaine without epinephrine
Study: 23668921
Drug: Postoperative subacromial
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative subacromial infusion catheter filled with saline solution
Study: 23668921
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative subacromial infusion catheter
Study: 23668921
Drug: Mean daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean daily oxycodone consumption
Study: 21545606
Drug: A3309 (0.1-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: A3309 (0.1-10 mg/day)
Study: 15500197
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg acetylsalicylic acid (ASA) + 60 mg pseudoephedrine (PSE)
Study: 15500197
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ASA + 30 mg PSE
Study: 15500197
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg paracetamol + 60 mg PSE (active control)
Study: 11222797
Drug: Monotherapy initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monotherapy initiation trials
Study: 7946584
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiation treatment
Study: 7946584
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment (at 8 months)
Study: 7946584
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (after 3 months)
Study: 30678556
Drug: High-ending tune
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-ending tune (L*+H L‐!H%)
Study: 30678556
Drug: Flat-ending tune
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flat-ending tune (L+H* L‐L%)
Study: 25049247
Drug: Posaconazole tablets
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole tablets
Study: 25760679
Drug: Phenylephrine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (100 μg + 0.5 μg kg(‐1) min(‐1))
Study: 23796191
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care intervention (20-minute session of behavioural change counselling, with potential referral to motivational enhancement therapy and local specialist alcohol services)
Study: 21362268
Drug: Transforming growth
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforming growth factor β receptor type II (TGFBRII) overexpression
Study: 11210993
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin plus bedtime subcutaneous ultralente insulin injection
Study: 11210993
Drug: Usual insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual insulin regimen of two to three injections per day
Study: 9701387
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (1000 mg 3 times per day)
Study: 8027275
Drug: Buserelin (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (twice a day for 15 days)
Study: 8027275
Drug: Triptorelin (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin (3.75 mg single dose 15 days before stimulation)
Study: 8027275
Drug: Triptorelin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin (0.1 mg daily for 4 weeks before stimulation)
Study: 2563730
Drug: BIM 23014
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIM 23014 (2 mg/12 h, constant sc infusion)
Study: 2563730
Drug: BIM 23014
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIM 23014 (2 mg/12 h, constant sc infusion) with GHRH (10 ng/kg.min iv)
Study: 4053513
Drug: Aspirin administration
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin administration
Study: 31559844
Drug: Fascial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascial therapy
Study: 24238397
Drug: SMS reminders
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS reminders (daily messages reminding them of aspects regarding taking their medication)
Study: 12951885
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g glucose ingestion during oral glucose tolerance test
Study: 7632121
Drug: Psychoeducational multiple‐family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational multiple‐family group treatment
Study: 7632121
Drug: Psychoeducational single‐family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational single‐family treatment
Study: 2565687
Drug: Isradipine alone
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine alone (1.25 and 2.5 mg twice daily)
Study: 2565687
Drug: Isradipine with
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine with guanfacine (1 mg daily after 8 weeks)
Study: 28918754
Drug: Ferritin level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferritin level above 4420 ng/ml
Study: 19116322
Drug: 1.05 g
Normalized name: AVC 1.05 GM Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.05 g E-EPA/d plus 0.15 g ethyl-docosahexaenoic acid/d (n = 59)
Study: 11161541
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (parenteral nutrition without lipids)
Study: 11161541
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (parenteral nutrition with lipids)
Study: 9550543
Drug: Selective β1‐adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective β1‐adrenoceptor antagonist atenolol (0.062 mg · kg‐1 body weight) administered immediately after exercise (EXAT)
Study: 9550543
Drug: Nonselective β‐adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonselective β‐adrenoceptor antagonist propranolol (0.15 mg · kg‐1 body weight) administered after exercise (EXPRO)
Study: 9550543
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection instead of β‐antagonist (EX)
Study: 9550543
Drug: Control with
Normalized name: Azo Bladder Control With Go Less
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control with selective β1‐adrenoceptor antagonist atenolol (REAT)
Study: 9550543
Drug: Control with
Normalized name: Azo Bladder Control With Go Less
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control with nonselective β‐adrenoceptor antagonist propranolol (REPRO)
Study: 2679236
Drug: Nicardipine (NIC)
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine (NIC) treatment group
Study: 2679236
Drug: NIC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIC treatment group with impaired LV function
Study: 2679236
Drug: NIC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIC treatment group
Study: 630909
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg fenfluramine plus a 1600 calorie diet
Study: 630909
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg fenfluramine
Study: 20672256
Drug: Group music
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group music intervention (12 sessions of 30 minutes each, twice a week for 6 weeks)
Study: 16784179
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg per day)
Study: 8953683
Drug: Biapenem 500
Normalized name: biapenem
DrugBank: Biapenem (DB13028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biapenem 500 mg every 8 h
Study: 8953683
Drug: Imipenem/cilastatin 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin 500 mg/500 mg every 6 h
Study: 9023498
Drug: Lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicylate 1.8 g
Study: 12974995
Drug: Placebo monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo monotherapy
Study: 8084248
Drug: Oral protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral protein load in Group I (reflux patients)
Study: 8084248
Drug: Oral protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral protein load in Group II (urinary infection patients)
Study: 8084248
Drug: Oral protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral protein load in Group III (healthy controls)
Study: 16435613
Drug: Spinal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal morphine
Study: 27882820
Drug: AXL1717 (AXL)
Normalized name: Humax axl adc
DrugBank: Enapotamab vedotin (DB16156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXL1717 (AXL) 300 or 400 mg daily BID
Study: 27882820
Drug: Docetaxel (DCT)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (DCT) 75 mg/m2 in three-week cycles
Study: 24386809
Drug: Long-term oxygen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oxygen therapy (LTOT) via nasal cannula, administered continuously every day for one year.
Study: 22893497
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise training (SET) on top of best medical treatment (BMT) for 6 months
Study: 15532380
Drug: Carvedilol (24.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (24.4 +/- 2.0 mg/day) + Fosinopril (2.5-40 mg/day)
Study: 15532380
Drug: Atenolol (44.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (44.1 +/- 5.1 mg/day) + Fosinopril (2.5-40 mg/day)
Study: 2670719
Drug: Magaldrate (antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magaldrate (antacid poor in aluminum)
Study: 2670719
Drug: Compound M
Normalized name: benzoin compound MISCELL TINCTURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound M 70 (antacid rich in aluminum)
Study: 31526767
Drug: Levodopa medication
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa medication (on medication)
Study: 31526767
Drug: Training off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training off levodopa medication (off medication)
Study: 26626800
Drug: S-1 (40-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (40-60 mg/m2 twice daily) for 2 weeks, followed by S-1 and oxaliplatin (100 mg/m2) for 8 cycles
Study: 25223844
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT), manualized exposure-based
Study: 21831418
Drug: Carboplatin and
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin and paclitaxel doublet chemotherapy (4 cycles: 3 weeks on treatment, 1 week off; carboplatin on day 1, paclitaxel on days 1, 8, and 15)
Study: 21831418
Drug: Vinorelbine or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine or gemcitabine monotherapy (5 cycles: 2 weeks on treatment, 1 week off)
Study: 21831418
Drug: Doublet chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublet chemotherapy
Study: 10722036
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (66 mg/kg per hour)
Study: 1333105
Drug: Unfractionated (UF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated (UF) heparin 5000 IU three times daily for 10 days
Study: 1333105
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight (LMW) heparin (CY 216 D) 3100 IU once daily for 10 days
Study: 27687678
Drug: 20 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/m2 cisplatin on 5 days every 4 weeks (group A)
Study: 27687678
Drug: 30-40 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-40 mg/m2 cisplatin weekly (group B)
Study: 21810108
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list control (delayed treatment group)
Study: 10912691
Drug: Topical adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical adrenaline application after myringotomy before tympanostomy tube placement
Study: 8259772
Drug: Etidronate therapy
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etidronate therapy (400 mg daily for 14 days, phosphate 1.0 g twice daily for 3 days, calcium 500 mg daily for the remainder of each 91-day cycle)
Study: 20434046
Drug: Etidronate therapy
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etidronate therapy
Study: 8259772
Drug: Open-label intermittent
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label intermittent cyclic etidronate therapy
Study: 3897204
Drug: Fluoxetine (55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (55 mg/day)
Study: 3897204
Drug: Amitriptyline (159
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (159 mg/day)
Study: 31818628
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg once daily for 3 weeks)
Study: 28177189
Drug: High cortisol
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cortisol (c. 1400 nM) with high insulin